Amarin (AMRN) Scheduled to Post Earnings on Wednesday

Amarin (NASDAQ:AMRN) is set to release its earnings data after the market closes on Wednesday, October 30th. Analysts expect Amarin to post earnings of ($0.05) per share for the quarter. Individual that wish to listen to the company’s earnings conference call can do so using this link.

Amarin Stock Performance

Shares of AMRN stock opened at $0.58 on Wednesday. Amarin has a twelve month low of $0.57 and a twelve month high of $1.37. The company’s 50-day moving average price is $0.60 and its 200-day moving average price is $0.73. The stock has a market cap of $237.37 million, a price-to-earnings ratio of -4.82 and a beta of 1.92.

Analysts Set New Price Targets

Separately, StockNews.com lowered shares of Amarin from a “buy” rating to a “hold” rating in a report on Thursday, July 4th.

Insiders Place Their Bets

In other Amarin news, CEO Aaron Berg purchased 160,000 shares of the firm’s stock in a transaction dated Friday, August 2nd. The shares were acquired at an average price of $0.64 per share, with a total value of $102,400.00. Following the purchase, the chief executive officer now directly owns 805,380 shares in the company, valued at approximately $515,443.20. This trade represents a 0.00 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. 1.96% of the stock is owned by insiders.

About Amarin

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.